NCI-H441 Cells for Lung Cancer Discoveries

NCI-H441 cells were derived from the papillary adenocarcinoma of a human male patient and constitute an epithelial cell line that is one of the foremost models researchers have for investigating the efficacy of inhalant-based cancer therapies. With delivery to the lungs much easier through airways in the human body, novel treatments may focus on delivering nucleic acids in non-cytotoxic transfection reagents to alveoli and other lung cells. NCI-H441 cells are known for doubling in population size under sixty hours, and express the major surfactant apoprotein, making them a unique environment for drug testing, lung cancer research, and siRNA screening for the development of gene therapies targeting late-stage lung cancer.